Dysfunctions associated with methylation, microrna expression and gene expression in lung cancer

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Huang, Tao ^b,c,f   Jiang, Min ^d,e   Kong, Xiangyin ^d,e   Cai, Yu Dong ^a  

^a SHANGHAI UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA;

ADULT; AGED; ARTICLE; CANCER GENETICS; CLASSIFICATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; GENE; GENE EXPRESSION; GENETIC DATABASE; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; RNA ANALYSIS; RNA METHYLATION; VALIDATION PROCESS;

AGED; CLUSTER ANALYSIS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER;

EID: 84865097377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043441     Document Type: Article

References (78)

1. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J, (2006) Cancer: a Systems Biology disease. Biosystems 83: 81-90.
2. Kreeger PK, Lauffenburger DA, (2010) Cancer systems biology: a network modeling perspective. Carcinogenesis 31: 2-8.
3. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
4. Ponomareva AA, Rykova E, Cherdyntseva NV, Choinzonov EL, Laktionov PP, et al. (2011) [Molecular-genetic markers in lung cancer diagnostics]. Mol Biol (Mosk) 45: 203-217.
5. Huang T, Wan S, Xu Z, Zheng Y, Feng KY, et al. (2011) Analysis and prediction of translation rate based on sequence and functional features of the mRNA. PLoS ONE 6: e16036.
6. Lee JH, Voortman J, Dingemans AM, Voeller DM, Pham T, et al. (2011) MicroRNA expression and clinical outcome of small cell lung cancer. PLoS ONE 6: e21300.
7. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, et al. (2010) MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70: 8288-8298.
8. Chari R, Coe BP, Wedseltoft C, Benetti M, Wilson IM, et al. (2008) SIGMA2: a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes. BMC Bioinformatics 9: 422.
9. Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL, (2010) An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. BMC Syst Biol 4: 67.
10. Peng J, Zhu J, Bergamaschi A, Han W, Noh D-Y, et al. (2010) Regularized multivariate regression for identifying master predictors with application to integrative genomics study of breast cancer. Annals Of Applied Statistics 4: 53-77.
11. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, et al. (2010) An integrated approach to uncover drivers of cancer. Cell 143: 1005-1017.
12. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
13. Christensen BC, Marsit CJ, Houseman EA, Godleski JJ, Longacker JL, et al. (2009) Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res 69: 6315-6321.
14. Tan X, Qin W, Zhang L, Hang J, Li B, et al. (2011) A Five-microRNA Signature for Squamous Cell Lung Carcinoma (SCC) Diagnosis and Hsa-miR-31 for SCC Prognosis. Clin Cancer Res.
15. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, et al. (2010) Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer.
16. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ, (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-144.
17. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
18. Betel D, Wilson M, Gabow A, Marks DS, Sander C, (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-153.
19. Sethupathy P, Corda B, Hatzigeorgiou AG, (2006) TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 12: 192-197.
20. Wang X, El Naqa IM, (2008) Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24: 325-332.
21. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
22. Huang T, Zhang J, Xie L, Dong X, Zhang L, et al. (2011) Crosstissue Coexpression Network of Aging. OMICS.
23. Huang T, Xu Z, Chen L, Cai YD, Kong X, (2011) Computational Analysis of HIV-1 Resistance Based on Gene Expression Profiles and the Virus-Host Interaction Network. PLoS ONE 6: e17291.
24. Huang T, Wang P, Ye ZQ, Xu H, He Z, et al. (2010) Prediction of Deleterious Non-Synonymous SNPs Based on Protein Interaction Network and Hybrid Properties. PLoS ONE 5: e11900.
25. Huang T, Shi XH, Wang P, He Z, Feng KY, et al. (2010) Analysis and prediction of the metabolic stability of proteins based on their sequential features, subcellular locations and interaction networks. PLoS ONE 5: e10972.
26. Huang T, Niu S, Xu Z, Huang Y, Kong X, et al. (2011) Predicting Transcriptional Activity of Multiple Site p53 Mutants Based on Hybrid Properties. PLoS ONE 6: e22940.
27. Huang T, Cui W, Hu L, Feng K, Li YX, et al. (2009) Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. PLoS ONE 4: e8126.
28. Huang T, Chen L, Liu X-J, Cai Y-D, (2011) Predicting triplet of transcription factor- mediating enzyme- target gene by functional profiles. Neurocomputing 74: 3677-3681.
29. Huang T, Chen L, Cai Y-D, Chou K-C, (2011) Classification and analysis of regulatory pathways using graph property, biochemical and physicochemical property, and functional property. PLoS ONE 6: e25297.
30. Cai Y, Huang T, Hu L, Shi X, Xie L, et al. (2011) Prediction of lysine ubiquitination with mRMR feature selection and analysis. Amino Acids.
31. Huang T, Tu K, Shyr Y, Wei CC, Xie L, et al. (2008) The prediction of interferon treatment effects based on time series microarray gene expression profiles. J Transl Med 6: 44.
32. Huang T, Zhang J, Xu ZP, Hu LL, Chen L, et al. (2012) Deciphering the effects of gene deletion on yeast longevity using network and machine learning approaches. Biochimie 94: 1017-1025.
33. Huang T, Zhang J, Xie L, Dong X, Zhang L, et al. (2011) Crosstissue coexpression network of aging. OMICS 15: 665-671.
34. Huang T, Chen L, Cai YD, Chou KC, (2011) Classification and analysis of regulatory pathways using graph property, biochemical and physicochemical property, and functional property. PLoS ONE 6: e25297.
35. Huang T, Wang J, Cai Y-D, Yu H, Chou K-C, (2012) Hepatitis C Virus Network Based Classification of Hepatocellular Cirrhosis and Carcinoma. PLoS ONE 7: e34460.
36. Huang T, Wang C, Zhang G, Xie L, Li Y, (2012) SySAP: a system-level predictor of deleterious single amino acid polymorphisms. Protein Cell 3: 38-43.
37. Babbar N HA, Huang Y, Casero RA Jr, (2006) Tumor necrosis factor alpha induces spermidine/spermine N1-acetyltransferase through nuclear factor kappaB in non-small cell lung cancer cells. J Biol Chem 281(34): 24182-24192.
38. Wesche J, Haglund K, Haugsten EM, (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437: 199-213.
39. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
40. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
41. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2: 62ra93.
42. Warburton D, El-Hashash A, Carraro G, Tiozzo C, Sala F, et al. (2010) Lung organogenesis. Curr Top Dev Biol 90: 73-158.
43. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, et al. (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216.
44. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ, (2007) Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 67: 7972-7976.
45. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, et al. (2011) EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 71: 3087-3097.
46. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104: 15805-15810.
47. Fruh M, (2011) The search for improved systemic therapy of non-small cell lung cancer-what are today′s options? Lung Cancer 72: 265-270.
48. Jiang L, Zhang Q, Chang J, Qiu X, Wang E, (2009) [hsa-miR-125a-5p Enhances Invasion Ability in Non-Small Lung Carcinoma Cell Lines.]. Zhongguo Fei Ai Za Zhi 12: 951-955.
49. Jiang L, Zhang Q, Chang H, Qiu X, Wang E, (2009) [hsa-miR-125a-5p Enhances Invasion in Non-small Cell Lung Carcinoma Cell Lines by Upregulating Rock-1.]. Zhongguo Fei Ai Za Zhi 12: 1069-1073.
50. Watanabe K, Emoto N, Hamano E, Sunohara M, Kawakami M, et al. (2012) Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer 130: 2580-2590.
51. Davies H, Hunter C, Smith R, Stephens P, Greenman C, et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595.
52. Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, et al. (2011) Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 59: 527-537.
53. Belinsky SA, (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717.
54. Selamat SA, Galler JS, Joshi AD, Fyfe MN, Campan M, et al. (2011) DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS ONE 6: e21443.
55. Belinsky SA, (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer 4: 707-717.
56. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
57. Chou RH, Lin SC, Wen HC, Wu CW, Chang WS, (2011) Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Commun 409: 442-447.
58. Liu L, Wu J, Wu C, Wang Y, Zhong R, et al. (2011) A functional polymorphism (-1607 1G-&2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer 117: 5172-5181.
59. Xiang X, Zhuang X, Ju S, Zhang S, Jiang H, et al. (2011) miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene 30: 3440-3453.
60. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, et al. (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535-8540.
61. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, et al. (2009) An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28: 2773-2783.
62. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1: 2005 0010.
63. Reinmuth N, Jauch A, Xu EC, Muley T, Granzow M, et al. (2008) Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 62: 193-201.
64. Sasaki H, Okuda K, Shimizu S, Takada M, Kawahara M, et al. (2009) EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol 135: 313-318.
65. Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, et al. (2009) Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol 135: 723-730.
66. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, et al. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10: 25-38.
67. Jo UH, Han SG, Seo JH, Park KH, Lee JW, et al. (2008) The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population. BMC Cancer 8: 359.
68. De Jong WK, Verpooten GF, Kramer H, Louwagie J, Groen HJ, (2009) Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer. Anticancer Res 29: 363-369.
69. Bastide K, Guilly MN, Bernaudin JF, Joubert C, Lectard B, et al. (2009) Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors. Lung Cancer 63: 348-353.
70. Katsuda K, Kataoka M, Uno F, Murakami T, Kondo T, et al. (2002) Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 21: 2108-2113.
71. Gregorc V, Darwish S, Ludovini V, Pistola L, De Angelis V, et al. (2003) The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. Lung Cancer 42: 275-281.
72. Dacic S, Kelly L, Shuai Y, Nikiforova MN, (2010) miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol 23: 1577-1582.
73. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, et al. (2008) MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27: 3845-3855.
74. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, et al. (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57.
75. Wang G, Mao W, Zheng S, (2008) MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 582: 3663-3668.
76. Cho WC, Chow AS, Au JS, (2009) Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 45: 2197-2206.
77. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, et al. (2009) miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 5553-5559.
78. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741.